Free Trial

IGM Biosciences (IGMS) Competitors

IGM Biosciences logo
$1.33 -0.02 (-1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 +0.01 (+0.75%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGMS vs. AVTE, AVIR, DBVT, ANNX, OLMA, RCKT, CMPS, AARD, ABEO, and GLUE

Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Aerovate Therapeutics (AVTE), Atea Pharmaceuticals (AVIR), DBV Technologies (DBVT), Annexon (ANNX), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), COMPASS Pathways (CMPS), Aardvark Therapeutics (AARD), Abeona Therapeutics (ABEO), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.

IGM Biosciences vs. Its Competitors

IGM Biosciences (NASDAQ:IGMS) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, IGM Biosciences had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for IGM Biosciences and 0 mentions for Aerovate Therapeutics. IGM Biosciences' average media sentiment score of 0.51 beat Aerovate Therapeutics' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
IGM Biosciences Positive
Aerovate Therapeutics Neutral

IGM Biosciences currently has a consensus target price of $5.50, indicating a potential upside of 313.53%. Given IGM Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IGM Biosciences is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IGM Biosciences
1 Sell rating(s)
9 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.90
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aerovate Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Aerovate Therapeutics' return on equity of -90.19% beat IGM Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IGM Biosciences-7,417.79% -317.97% -71.43%
Aerovate Therapeutics N/A -90.19%-77.47%

42.8% of IGM Biosciences shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

IGM Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Aerovate Therapeutics has lower revenue, but higher earnings than IGM Biosciences. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM Biosciences$2.68M29.67-$195.79M-$3.27-0.41
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-6.15

Summary

IGM Biosciences beats Aerovate Therapeutics on 9 of the 14 factors compared between the two stocks.

Get IGM Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IGMS vs. The Competition

MetricIGM BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$80.70M$2.88B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-0.417.5719.7120.50
Price / Sales29.67286.98435.75120.29
Price / CashN/A41.1936.8257.86
Price / Book1.627.487.985.56
Net Income-$195.79M-$55.04M$3.16B$248.40M
7 Day Performance3.10%5.44%3.69%6.04%
1 Month Performance0.76%2.38%2.91%7.69%
1 Year Performance-80.15%5.53%34.30%20.97%

IGM Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IGMS
IGM Biosciences
4.3971 of 5 stars
$1.33
-1.5%
$5.50
+313.5%
-78.5%$80.70M$2.68M-0.41190
AVTE
Aerovate Therapeutics
N/A$11.14
+3.1%
N/A-80.2%$322.89MN/A-3.7320High Trading Volume
AVIR
Atea Pharmaceuticals
2.3212 of 5 stars
$3.64
-2.7%
$6.00
+64.8%
+12.0%$320.07MN/A-2.2170
DBVT
DBV Technologies
3.7165 of 5 stars
$11.01
-5.1%
$14.75
+34.0%
+162.5%$317.72M$4.15M-2.2480Analyst Upgrade
ANNX
Annexon
2.6642 of 5 stars
$2.73
-5.5%
$12.50
+357.9%
-39.2%$317.08MN/A-2.3160Positive News
OLMA
Olema Pharmaceuticals
1.7308 of 5 stars
$4.45
-2.6%
$24.50
+450.6%
-58.3%$312.68MN/A-2.2170Positive News
RCKT
Rocket Pharmaceuticals
4.8505 of 5 stars
$2.81
-3.1%
$18.60
+561.9%
-85.9%$309.68MN/A-1.07240Trending News
CMPS
COMPASS Pathways
2.2028 of 5 stars
$3.31
+1.5%
$17.00
+413.6%
-46.6%$305.01MN/A-1.66120
AARD
Aardvark Therapeutics
N/A$13.92
flat
$33.00
+137.1%
N/A$302.01MN/A0.0018
ABEO
Abeona Therapeutics
3.986 of 5 stars
$5.75
-2.4%
$19.25
+234.8%
+26.7%$301.31M$3.50M-4.5390
GLUE
Monte Rosa Therapeutics
1.3398 of 5 stars
$4.97
+2.1%
$15.33
+208.5%
+36.5%$299.55M$75.62M62.1390Positive News

Related Companies and Tools


This page (NASDAQ:IGMS) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners